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OBJECTIVE — The purpose of this study was to elucidate the mechanisms of diabetes re-
versibility after malabsorptive bariatric surgery.
RESEARCH DESIGN AND METHODS — Peripheral insulin sensitivity and -cell
function after either intravenous (IVGTT) or oral glucose tolerance (OGTT) tests and minimal
model analysis were assessed in nine obese, type 2 diabetic subjects before and 1 month after
biliopancreatic diversion and compared with those in six normal-weight control subjects. Insu-
lin-dependent whole-body glucose disposal was measured by the euglycemic clamp, and glu-
cose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) were
also measured.
RESULTS — TheﬁrstphaseofinsulinsecretionaftertheIVGTTwasfullynormalizedafterthe
operation. The disposition index from OGTT data was increased about 10-fold and became
similar to the values found in control subjects, and the disposition index from IVGTT data
increasedabout3.5-fold,similarlytowhathappenedaftertheeuglycemicclamp.Theareaunder
thecurve(AUC)forGIPdecreasedaboutfourtimes(from3,000816to577155pmol l
1 
min, P  0.05). On the contrary, the AUC for GLP1 almost tripled (from 150.4  24.4 to
424.464.3pmol l
1 min,P0.001).NosigniﬁcantcorrelationwasfoundbetweenGIPor
GLP1 percent changes and modiﬁcation of the sensitivity indexes independently of the route of
glucose administration.
CONCLUSIONS — Restoration of the ﬁrst-phase insulin secretion and normalization of
insulin sensitivity in type 2 diabetic subjects after malabsorptive bariatric surgery seem to be
related to the reduction of the effect of some intestinal factor(s) resulting from intestinal bypass.
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n 1987, Pories et al. (1) published a
stunning observation that 99% of mor-
bidly obese patients with frank type 2
diabetes or impaired glucose tolerance
who had undergone Roux-en-Y gastric
bypass (RYGB) became and remained eu-
glycemicaftersurgery.Mostinterestingly,
these authors reported that the patients
were converted to euglycemia within 10
days,eveniftheyhadrequiredlargedoses
of insulin.
Subsequently, we (2,3) and other au-
thors(4)havefoundthateitherrestrictive
ormalabsorptivebariatricsurgeryiseffec-
tive in improving/resolving type 2 diabe-
tes. In particular, using the euglycemic
hyperinsulinemic clamp we have demon-
strated that insulin sensitivity was nor-
malized after malabsorptive bariatric
surgery in both obese type 2 diabetic (2)
and obese normotolerant subjects.
We theorized that the normalization
ofinsulinsensitivitythatoccursveryearly
after biliopancreatic diversion (BPD) be-
foreasigniﬁcantweightlosscanoccur(2)
may be dependent on the hormonal
changes related to the nutrient diversion
from the duodenum, the entire jejunum,
and the proximal portion of the ileum. In
fact, the enteroendocrine cells are largely
foundinthesetractsofthesmallintestine.
Two main hypotheses have been ad-
vanceduptonowtoexplainwhichpartof
the small intestine is implicated in the re-
versibility of diabetes. The ﬁrst, known as
the hindgut hypothesis (5), holds that di-
abetes control results from accelerated
delivery of nutrients in the distal small
intestine. The second, the so-called fo-
reguthypothesis,statesthattheexclusion
of duodenum and jejunum from nutrient
transit might prevent the secretion of a
putative signal that promotes insulin re-
sistance (2,6). The balance between the
stimulatory action on insulin secretion
exerted by incretins and the anti-incretin
effect might allow a ﬁner control of the
glucose disposal.
To test the hypothesis that an imbal-
ance in the release of intestinal hor-
mone(s) can determine insulin resistance
and that after BPD secretion of intestinal
hormone(s) is reduced, allowing normal-
ization of insulin sensitivity with subse-
quent -cell glucose sensitivity
improvement, we assessed peripheral in-
sulin sensitivity and -cell function after
either an intravenous or oral glucose tol-
erance test in nine obese, type 2 diabetic
subjects compared with those in six nor-
mal-weight age- and sex-matched control
subjects. To further support our results,
insulin-dependent whole-body glucose
disposal was also measured by the eugly-
cemic clamp.
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METHODS— Nine (ﬁve women and
four men) morbidly obese (BMI 51.7 
8.1 kg/m
2, age 41  9 years
[mean  SD]), type 2 diabetic patients
and six normotolerant (according to the
American Diabetes Association criteria
[7]) sex- and age-matched volunteers
(threewomenandthreemen,BMI24.6
1.3 kg/m
2, age 39  7 years) were stud-
ied. The patients were all characterized as
having type 2 diabetes according to the
American Diabetes Association criteria.
A1C ranged from 7.5 to 9.5%.
At the time of the baseline study, all
subjects were consuming a diet with the
following average composition: 60% car-
bohydrate,30%fat,and10%protein(1
g/kg body weight). This dietary regimen
was maintained for 1 week before the
study. In all patients, an oral glucose tol-
erance test (OGTT), an intravenous glu-
cose tolerance test (IVGTT), and a
euglycemic hyperinsulinemic clamp
(EHC) were randomly performed within
1monthbeforesurgeryand1monthafter
surgery. The healthy volunteers also un-
derwent the same tests. All patients re-
ceived the same parenteral nutrition
regimen (7,100 kJ/day) during the ﬁrst
6daysaftersurgery;thentheywerefreeto
consume a normal diet.
The study protocol was approved by
the institutional ethics committee of the
Catholic University of Rome. The nature
and purpose of the study were carefully
explained to all subjects before they pro-
vided their written consent to participate.
Body composition
On a separate day, total body water
(TBW) was determined using 0.19 MBq
3H2O in 5 ml of saline administered as an
intravenous bolus injection. Blood sam-
ples were drawn before and 3 h after the
injection. Radioactivity was determined
in duplicate on 0.5 ml plasma in a -scin-
tillation counter (model 1600TR; Can-
berra-Packard, Meriden, CT).
Corrections were made for nonaqueous
hydrogen exchange. Water density at
body temperature was assumed to be
0.99371 kg/l. TBW (kilograms) was com-
puted as
3H2O dilution space (liters) 
0.950.99371.Fat-freemass(FFM)was
obtained by dividing TBW by 0.732 (8).
OGTT
After an overnight fast, a standard 75-g
OGTT was performed in each patient at
baselineandwithin1monthaftersurgery
as well as in each volunteer, with blood
sampling at 0, 30, 60, 90, 120, 150, 180,
and 240 min. Samples were placed in
chilled tubes, and plasma was separated
within 20 min and stored at 70°C.
IVGTT
An IVGTT was performed preoperatively
and within 1 month postoperatively. At
8:00–9:00 A.M., after a 12-h overnight
fast,anintravenouscatheterwasplacedin
one antecubital vein and an intravenous
bolus of 0.33 g glucose/kg body weight as
50% water solution was injected in the
contralateral antecubital vein. Blood sam-
ples were obtained at 15, 5, 2, 4, 6, 8,
10, 12, 14, 16, 18, 20, 25, 30, 40, 50, 60,
70, 80, 100, 120, 140, 160, 180, and 240
min relative to the start of dextrose injec-
tion. Samples were placed in chilled
tubes, and plasma was separated within
20 min and stored at 70°C.
EHC
Peripheral insulin sensitivity was evalu-
atedbytheEHC(9)atbaselineandwithin
4 weeks after surgery. After a cannula was
inserted in a dorsal hand vein for sam-
pling arterialized venous blood and an-
other in the antecubital fossa of the
contralateral arm for infusions, the sub-
jects rested in the supine position for at
least1h.Theywereplacedwithonehand
warmed in a heated-air box set at 60°C to
obtain arterialized blood samples. Insulin
sensitivity, as the total insulin-mediated
glucose uptake, was determined during a
primed constant infusion of insulin at the
rateof6pmol min
1 kg
1.Tomaintain
the glycemia in a normal range, rapid in-
sulin and potassium phosphate in saline
were infused overnight before BPD. The
plasma glucose concentration was
clamped at 5.1  0.5 mmol/l (mean 
SD) before and at 3.9  0.4 mmol/l after
BPD, respectively, throughout the insulin
infusion by means of a variable glucose
infusion and blood glucose determina-
tions every 5 min. Insulin sensitivity
was determined during the last 40 min
of the clamp by computing the whole-
body glucose uptake (micromoles per
minute per kilogram of FFM) or the
clearance rate (milliliters per minute per
kilogram of FFM) during steady-state eu-
glycemic hyperinsulinemia.
BPD
Thismalabsorptivesurgicalprocedure(2)
consists of an 60% distal gastric resec-
tion with stapled closure of the duodenal
stump. The residual volume of the stom-
ach is about 300 ml. The small bowel is
transected at 2.5 m from the ileocecal
valve, and its distal end is anastomosed to
theremainingstomach.Theproximalend
of the ileum, comprising the remaining
small bowel (involved in carrying bilio-
pancreatic juice but excluded from food
transit), is anastomosed in an end-to-side
fashion to the bowel, 50 cm proximal to
the ileocecal valve. Consequently, the to-
tal length of absorbing bowel is reduced
to 250 cm, the ﬁnal 50 cm of which, the
so-called common channel, represents
thesitewhereingestedfoodandbiliopan-
creatic juices mix.
Analytical procedures
Plasma glucose was measured by the glu-
coseoxidasetechniqueonaBeckmanglu-
cose analyzer (Beckman, Fullerton, CA).
Plasma insulin was assayed by a micro-
particle enzyme immunoassay (Abbott,
Pasadena,CA)withsensitivityof1U/ml
and intra-assay coefﬁcient of variation
(CV) of 6.6%. C-peptide was assayed by
radioimmunoassay (MYRIA; Technoge-
netics, Milan, Italy); this assay has a min-
imal detectable concentration of 17
pmol/l and intra-assay and inter-assay
CVs of 3.3–5.7 and 4.6–5.3%, respec-
tively.
Total glucose-dependent insulino-
tropic polypeptide (GIP) was measured
by ELISA (Linco). The assay is 100% spe-
ciﬁcforGIP1–42andGIP3–42anddoes
not cross-react with glucagon-like pep-
tide (GLP)-1, GLP-2, oxyntomodulin, or
glucagon. The intra-assay and inter-assay
CVs were 3.0–8.8 and 1.8–6.1%, re-
spectively. Active GLP-1, an indicator of
potential action, was measured by ELISA
(Linco). The intra-assay and inter-assay
CVs were 3–7 and 7–8%, respectively.
The assay is 100% speciﬁc for GLP-1(7–
36) and GLP-1(7–37) and does not react
with GLP-1(9–36), glucagon, or GLP-2.
Mathematical model
The OGTT and IVGTT minimal models
(10) were used to compute the insulin
sensitivity (SI). The indexes of -cell sen-
sitivitytoglucosefortheIVGTT(theﬁrst-
phase -cell sensitivity, 1, and the
second-phase sensitivity, 2) and for the
OGTT (the dynamic -cell sensitivity,
d, the static sensitivity, s, and the total
sensitivity, ) were computed by the C-
peptide minimal model as proposed by
Toffolo et al. (11) and Breda et al. (12).
Thedispositionindex(DI)wascomputed
as SI. The model parameters were
estimated by minimization of a weighted
least-squares index using a constrained
Differential response to glucose load after BPD
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tine of the MATLAB library. The standard
errors of the estimates of individual pa-
rameters were evaluated by the Jackknife
method (3), and the coefﬁcients of varia-
tion were found to be 20%.
Statistics
All of the data are expressed as means 
SEM unless otherwise speciﬁed. The Wil-
coxonpaired-sampletestandANOVAfor
repeated measurements, followed by the
Tukey test, were used for intragroup and
intergroup comparisons, respectively.
Two-sided P  0.05 was considered sig-
niﬁcant. Nonparametric Spearman corre-
lations (SPSS for Windows version 10)
were used to assess linear relationships
between single variables.
RESULTS— A small, but signiﬁcant,
weight loss (from 153.1  34.2 to
143.5  32.8 kg [mean  SD], P  0.01)
was observed 1 month after BPD.
The OGTT glucose incremental area
under the curve (	AUC) signiﬁcantly
(P  0.02) decreased after BPD from
0.740.08to0.220.0410
3mmol/l
  min, becoming not statistically different
from that of control subjects. Insulin
	AUC decreased from 3.83  0.99 to
1.01  0.28  10
4 pmol   l
1   min (P 
0.02),reachingavaluecomparabletothat
of healthy control subjects (NS). Finally,
the C-peptide 	AUC declined from
2.480.35to1.100.3410
2nmol/l
  min (P  0.02); its value in control sub-
jects was 1.71  0.36  10
2 nmol/l   min
(NS).
In the IVGTT also, the 	AUC of glu-
cose signiﬁcantly decreased from 0.63 
0.08 to 0.51  0.06  10
3 mmol   l
1
min (P  0.05) (control subjects 0.31 
0.02  10
3 mmol   l
1   min, NS). Simi-
larly, insulin 	AUC decreased from
3.66  0.65 to 1.90  0.27  10
4 pmol
  l
1   min (P  0.02) (control subjects
0.50  0.06  10
4 pmol   l
1   min). C-
peptide 	AUC did not change signiﬁ-
cantly (from 1.63  0.28 to 1.54 
0.50  10
2 nmol   l
1   min, NS); how-
ever,thelatterwasnotstatisticallydissim-
ilar from that in control subjects (0.85 
0.16  10
2 nmol   l
l   min, NS), proba-
bly as a consequence of a rather large
SEM.
The estimates of the indexes com-
puted by the oral and intravenous math-
ematical models are reported in Table 1.
The ﬁrst phase of insulin secretion was
fully normalized after BPD, as shown in
Table 1 by the marked increase of the 1
index. Figure 1 shows the recovery of the
ﬁrst phase of the insulin secretion rate in
theIVGTT.Thedynamicsensitivityindex
also showed a tendency to increase after
BPD.
BeforeBPD,theinsulinsensitivityde-
termined by the OGTT was signiﬁcantly
smaller than that found by the IVGTT or
the euglycemic clamp (Table 1), with the
M value increasing from 27.7  6.4 to
77.920.0mol kgFFM
1 min
1after
BPD (P  0.0001). However, 1 month
after BPD, insulin sensitivity reached val-
ues comparable to those found in control
subjects,independentlyoftheglucosead-
ministration route. In particular, a three-
fold increase in the insulin sensitivity
estimated by either the IVGTT minimal
model or the EHC was observed, whereas
the same index computed by the OGTT
minimal model was raised six times (P 
0.05). The DI, calculated by the OGTT,
was increased 10-fold and became sim-
ilar to the values found in control sub-
jects, whereas the DI calculated by the
IVGTT increased about 3.5 times.
The time courses of GIP and GLP-1
during the OGTT are reported in Fig. 2.
GIP peaked earlier after than before BPD,
i.e., 30 min compared with 60 min. The
	AUCGIP(meanSEM)decreasedabout
four times, from 3,000  816 pmol  
l
1   min preoperatively to 577  155
pmol   l
1   min postoperatively (P 
0.05). On the contrary, the 	AUCGLP1
was almost tripled, from 150  24 to
424  64 pmol   l
1   min (P  0.001).
The 	AUC of both GLP1 and GIP in
control subjects (392  11 and 983 
77pmol l
1 min,respectively)werenot
statistically different from the values ob-
served in diabetic patients after BPD.
No signiﬁcant correlation was found
between the percent change in the AUCs
of GIP and GLP-1 and the modiﬁcation of
the oral sensitivity index.
CONCLUSIONS — The principal
ﬁndings of our study are that 1) the ﬁrst-
phase insulin secretion was restored 1
month after BPD (1), 2) the -cell glu-
cose sensitivity was fully normalized, 3)
Table 1—Estimates of the indexes computed by the oral and the intravenous mathematical
models
Control
subjects
Diabetic subjects
before BPD
Diabetic subjects
after BPD
Indexes OGTT
SI  10
2 (ml   min
1   kgFFM
1  
pmol
1   l)
2.70  0.98 0.64  0.19 3.60  0.97*
SI post/SI pre 6.3  3.1
d  10
9 500  140 203  144 480  365
s  10
9 (min
1) 39.2  20.8 23.0  10.0 32.0  16.0
10
9 (min
1) 47.7  24.3 25.9  11.2 37.7  12.0#
AUCISR (nmol   m
2) 33.4  12.8 62.3  28.4 37.2  13.3¶
DI  10
14 (dl   min
2  
kgFFM
1   pmol
1   l)
1,197  599 148  51 1,227  276¶
Indexes IVGTT
SI  10
2 (ml   min
1   kgFFM
1  
pmol
1   l)
2.10  0.80 1.04  0.28 2.70  0.60§
SI post /SI pre 2.7  1.1
1  10
9 242  199 27.9  17.1 164  119§
2  10
9 (min
1) 10.2  2.9 10.0  4.8 12.5  8.5
10
9 (min
1) 16.6  5.3 10.8  5.2 16.5  9.5#
AUCISR (nmol   m
2) 23.9  3.7 43.9  22.8 41.9  21.7
DI  10
14 (dl   min
2  
kgFFM
1   pmol
1   l)
341  124 118  78 453  318§
Indexes EHC
SI  10
2 (ml   min
1   kgFFM
1  
pmol
1   l)
1.4  0.7 4.5  1.5
SI post /SI pre 3.5  1.2
Data are means  SD. OGTT (after/before): *P  0.005; #P  0.05; ¶P  0.02. Diabetic subjects after
BPD/control subjects: NS. IVGTT (after/before): §P  0.01; #P  0.05. Diabetic subjects after BPD/control
subjects: NS. EHC: SI before BPD is signiﬁcantly different from SI (OGTT) (P  0.001). SI (OGTT) and SI
(IVGTT)beforeBPDaresigniﬁcantlydifferent(P0.05);SI(EHC),SI(OGTT),andSI(IVGTT)afterBPDare
not signiﬁcantly different.
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malization of insulin sensitivity and the
consequent reduced requirement of insu-
lin secretion, and 4) the increase in the
insulin sensitivity estimated by the OGTT
minimal model was larger than that esti-
mated by the IVGTT minimal model.
The association of -cell dysfunc-
tion with insulin resistance represents
the main pathophysiological defect re-
sponsible for the development of type 2
diabetes. The -cell function in type 2
diabetes is characterized by a progres-
sive decline, from a net reduction to the
disappearance of the ﬁrst phase of glu-
cose-induced insulin secretion to the
impairment of the second-phase insulin
secretion. The early insulin response dis-
appears, even in the early stages of the dis-
ease, when fasting glucose concentrations
are only slightly higher than normal. This
defectisimportantbecauseﬁrst-phaseinsu-
lin secretion seems to have the greatest im-
pact on postprandial plasma glucose
excursions (13), determining postmeal
hyperglycemia.
Actually, the causes of this -cell
dysfunction are not completely known.
Autopsy studies have shown that 20–
50% of the -cells may have been lost
after many years of disease (14). How-
ever, there is experimental evidence
that a 65% partial pancreatectomy in
dogs reduces the maximum secretive
pancreaticinsulinresponse,butthatthe
residual pancreatic -cells become
more sensitive to glucose, thus provid-
ing partial compensation (15). There-
fore, Porte and Kahn (16) noted that
“the loss of -cell function is dispropor-
tionately more important than the de-
gree of -cell loss.“ Furthermore, there
is more recent evidence from the au-
topsy of type 2 diabetic patients that the
-cell mass is not signiﬁcantly dimin-
ished in most patients and that -cells
maintain active insulin gene transcrip-
tion and translation even in amyloid-
containing islets. This ﬁnding suggests
thatthemaindefectresidesinanabnor-
mal coupling of insulin secretion to gly-
cemia (17).
It is interesting to note that in the
present investigation the ﬁrst-phase insu-
lin secretion impairment was reversible
after BPD, when the body weight was re-
ducedonlyontheorderof6%.Briatore
et al. (18) have recently reported that the
acute insulin response (AIR) after IVGTT
was signiﬁcantly increased after BPD in
morbidly obese, type 2 diabetic subjects.
However, being based on insulin concen-
tration, AIR does not correspond directly
to the ﬁrst phase of insulin secretion, as it
alsoreﬂectsthehepaticinsulinextraction.
Because the hepatic extraction differs de-
pending on the pattern and amount of
insulin release, AIR does not provide an
independent assessment of insulin secre-
tion. Furthermore, insulin clearance ap-
peared to be signiﬁcantly reduced before
BPD, according to recently published
ﬁndings (19).
Recently, Henquin et al. (20) clearly
showed that the ﬁrst-phase insulin secre-
tion, which was absent in vivo in mice
withadoubleknockoutforisletantigen2
and 2 (21), was fully restored in the is-
lets of the same animals studied in vitro.
Thus, these authors (20) suggested the
existence of factors, extrinsic to the islets,
that can inhibit the in vivo insulin re-
sponse to an intraperitoneal glucose chal-
lenge. In analogy with the hypothesis of
Henquinetal.(20),wesuggestthata“fac-
tor” inhibiting insulin secretion can be
produced in the small intestine and that
the intestinal bypass, as occurs in BPD,
can reduce/suppress its synthesis and/or
delivery into the circulatory stream, al-
lowing the restoration of the ﬁrst-phase
insulin secretion.
It has been shown that a 3-h syn-
thetic GLP-1 infusion in type 2 diabetic
individuals was able to increase the AIR
after an IVGTT from 197  97 to
1,141  409 pmol   l
1   min, which,
however, was still seven times lower
than the levels reached in healthy con-
trol subjects (22). The corresponding
circulating levels of GLP1 were on the
orderof40–50pmol/l.Inourseries,the
Figure 1— IVGTT data (mean  SEM). Glucose (A) and insulin (B) plasma concentrations
before(grayshadedline)andafter(solidline)BPD.Insulinsecretionrate(ISR)(C)andC-peptide
data points with the ﬁtting curves superimposed (D). Before BPD: gray shaded lines and f; after
BPD: solid lines and Œ. Because of the overlapping of SEM bars, only mean values of C-peptide
data are reported.
Figure2—GIPandGLP-1concentrationsduringOGTTindiabeticpatientsbefore(f)andafter
(Œ) BPD.
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malized, whereas the circulating GLP1
reached levels of about 35 pmol/l, sug-
gesting that other mechanisms, such as
the presence of still unrecognized intes-
tinal factor/s can play a role in normal-
izing insulin secretion.
This very factor, or even another
factor secreted by the small intestine,
may also determine the insulin resis-
tance. In fact, insulin sensitivity was
fullynormalizedafterBPDwhenasmall
but signiﬁcant weight loss was
achieved. In support of this hypothesis,
we have found that the insulin-
mediated glucose uptake was signiﬁ-
cantly higher after BPD when the
glucoseloadwasadministeredorallyin-
stead of intravenously. Dalla Man et al.
(23) have shown that insulin action on
glucose disposal estimated by the oral
minimal model (SI*) was almost identi-
cal to that measured by a euglycemic
hyperinsulinemic clamp (SI*
clamp), sug-
gesting that the glucose disposal com-
ponent of the oral glucose minimal
model was well described. Therefore, at
least in healthy control subjects, the
OGTT minimal model of glucose kinet-
ics provides estimates of insulin action
equivalent to those with the euglycemic
clamp. This observation reinforces our
ﬁndings that after BPD insulin sensitiv-
ity increases much more after an oral
than an intravenous glucose challenge.
Furthermore, insulin resistance before
bariatric surgery was much higher after
an oral than after an intravenous glu-
cose load. Therefore, the anatomical
changes induced by the operation led to
a complete inversion of the insulin sen-
sitivity response, depending on the
route of glucose administration.
Toourknowledge,veryfewdataare
found in the literature for insulin sensi-
tivity after RYGB, and these were mea-
sured mostly by empirical methods and
thus are not easily comparable to the
present results. We reported previously
(24) that insulin-mediated glucose up-
take, measured by the EHC, did not
change signiﬁcantly after RYGB,
whereas it was dramatically increased
after BPD in normotolerant, morbidly
obese patients, becoming even higher
than that reported in healthy subjects.
Burstein et al. (25) observed a signiﬁ-
cant increase in the glucose metabolic
clearance rate, from a mean baseline
value of 3.0  1.6 to 6.7  3.9 ml   kg
1  
min
1 after RYGB (P  0.02), which,
however,asnotedbytheauthors,wasnot
completely reversed to normality.
WenotethattheGLP-1plasmacon-
centration was increased about three-
fold after BPD; however, neither the
changes in GLP-1 plasma levels nor
those in GIP explained the normaliza-
tion of insulin sensitivity. This fact
might suggest the existence of other in-
testinal factors in the control of insulin
action in peripheral tissues, whose se-
cretion is inhibited by surgery-induced
nutrient diversion.
In summary, restoration of ﬁrst-
phase insulin secretion as well as nor-
malization of the insulin sensitivity in
type 2 diabetic subjects after malab-
sorptive bariatric surgery seems to be
related to a reduction in the effect of
some intestinal factor(s) as a conse-
quence of intestinal bypass.
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